US4725585A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of enhancing the host defense
Assignee: Pfizer Health AB
•
Filing: 1985-09-20
•
Granted: 1988-02-16
•
Expires: 2005-09-20
Abstract
Abstract The invention relates to a method of enhancing or regulating the host defense of a mammal, said method comprising administering to a mammal a therapeutically effective amount of hyaluronic acid.
Inventors
- 👤 Per S. W. Wenge
- 👤 Lena D. Hakansson
- 👤 Henning R. Hallgren
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 20:06
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
44 words
A method for normalizing a reduced phagocytic activity exerted by the granulocytes of a mammal, comprising administering subcutaneously or intramuscularly to said mammal a non-antigenic hyaluronic acid preparation containing hyaluronic acid or a physiologically acceptable salt of said acid in a therapeutically effective amount.
Claim 2
Independent Claim
44 words
A method for normalizing a reduced phagocytic activity exerted by the granulocytes of a mammal, comprising administering subcutaneously or intramuscularly to said mammal a non-antigenic hyaluronic acid preparation containing hyaluronic acid or a physiologically acceptable salt of said acid in a therapeutically effective amount.
Claim 3
Dependent Claim
22 words
The method according to claim 1, wherein said effective amount comprises 1-40 mg of hyaluronic acid or a physiologically acceptable salt thereof.
Claim 4
Independent Claim
41 words
A method for treating or preventing infections associated with reduced phagocytic activity, in mammals, comprising administering subcutaneously or intramuscularly to a mammal a therapeutically effective amount of a non-antigenic hyaluronic acid preparation containing hyaluronic acid or a physiologically acceptable salt thereof.
Claim 5
Independent Claim
41 words
A method for treating or preventing infections associated with reduced phagocytic activity, in mammals, comprising administering subcutaneously or intramuscularly to a mammal a therapeutically effective amount of a non-antigenic hyaluronic acid preparation containing hyaluronic acid or a physiologically acceptable salt thereof.
Claim 6
Dependent Claim
22 words
The method according to claim 3, wherein said effective amount comprises 1-40 mg of hyaluonic acid or a physiologically acceptable salt thereof.
Claim 7
Dependent Claim
17 words
The method according to claim 3, wherein the mammal to be treated exhibits reduced granulocyte phagocytic activity.
Claim 8
Dependent Claim
17 words
The method according to claim 4, wherein the mammal to be treated exhibits reduced granulocyte phagocytic activity.
Claim 9
Dependent Claim
10 words
The method claim 1, wherein the mammal is a human.
Claim 10
Dependent Claim
11 words
The method of claim 3, wherein said mammal is a human.
Claim 11
Independent Claim
35 words
A method for treating infections in humans associated with reduced phagocytic activity, comprising administering subcutaneously or intramuscularly to a human a therapeutically effective amount of a non-antigenic hyaluronic acid or a physiologically acceptable salt thereof.
Claim 12
Independent Claim
35 words
A method for treating infections in humans associated with reduced phagocytic activity, comprising administering subcutaneously or intramuscularly to a human a therapeutically effective amount of a non-antigenic hyaluronic acid or a physiologically acceptable salt thereof.
Claim 13
Dependent Claim
16 words
The method according to claim 9, wherein the human to be treated exhibits reduced granulocytic activity.
Claim 14
Dependent Claim
22 words
The method according to claim 9, wherein said effective amount comprises 1-40 mg of hyaluronic acid or a physiologically acceptable salt thereof.
Claim 15
Dependent Claim
16 words
The method according to claim 11, wherein the human to be treated exhibits reduced granulocytic activity.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-02-15 | 1991-08-17 | 1992-02-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-02-15 | 1995-08-17 | 1996-02-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-02-15 | 1999-08-17 | 2000-02-16 | $7700.00 | Window Closed / Lapsed |